← Home

ONE

Healthcare & BiotechNEUTRAL

$0.175

as of 2026-09-09

5d return

-12.5%

20d return

+9.4%

60d return

+2.9%

RSI 14

52.4

vs 52w high

-56.3%

vs 52w low

+34.6%

SMA 20

Below

SMA 50

Above

Price · Volume · Broker flow
Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike.
Loading chart…
Closest correlates
Pearson r on log returns, window: 82d
  • GA8r=0.29, window: 82d
  • GEDr=0.26, window: 82d
  • DTIr=0.24, window: 82d
  • AISr=0.24, window: 82d
  • ZEUr=0.23, window: 82d
Announcements — last 30 days
  • 2026-08-27Continuous Disclosure Policy Update
  • 2026-08-27PSotherHalf Year 2026 Investor Presentation

    Oneview Healthcare released H1 2026 half-year results with execution commentary on scalable growth; the 3.7× volume spike and institutional accumulation (+$5m net 5-day flow) suggest material investor interest, though the 13% pre-announcement run suggests market anticipation of positive operational progress.

  • 2026-08-27PSmre_updateHalf Yearly Report and Accounts

    Oneview is shifting toward higher-margin recurring revenue (+13%) despite total revenue headwinds, with gross margin expanding to 70% and operating losses improving 30% YoY. However, cash runway remains tight at €7.2m against €5.5m half-year burn, with a critical A$7m Tranche 2 placement pending shareholder approval in H2 2026.